Bringing the Oncology Community Together

Renal Cell Carcinoma

Latest Renal Cell Carcinoma Articles View more >>
Unprecedented Changes in Oncology: Toward a New Dawn
Unprecedented Changes in Oncology: Toward a New Dawn
“Are you making progress?” is one of the questions you are most frequently being asked as an oncologist—even in social settings.
PD-L1 Expression Independent Prognostic Indicator in mRCC
PD-L1 Expression Independent Prognostic Indicator in mRCC
High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.
ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies
ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies
A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.
TKI Treatment Choices in mRCC Often Hinge on Dosing, Toxicities
TKI Treatment Choices in mRCC Often Hinge on Dosing, Toxicities
During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.
Personalized Medicine Takes Another Step Forward
Personalized Medicine Takes Another Step Forward
Like you, I get up every day and look at the stack of journals I know I need to read but cannot imagine when I will find the time.
Interactive Publication
Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.